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Synaptic and cellular changes induced by the schizophrenia
susceptibility gene G72 are rescued by N-acetylcysteine
treatment
B Pósfai1,4, C Cserép1,4, P Hegedüs1, E Szabadits1, DM Otte2, A Zimmer2, M Watanabe3, TF Freund1 and G Nyiri1
Genetic studies have linked the primate-specific gene locus G72 to the development of schizophrenia and bipolar disorder.
Transgenic mice carrying the entire gene locus express G72 mRNA in dentate gyrus (DG) and entorhinal cortex, causing altered
electrophysiological properties of their connections. These transgenic mice exhibit behavioral alterations related to psychiatric
diseases, including cognitive deficits that can be reversed by treatment with N-acetylcysteine, which was also found to be effective
in human patients. Here, we show that G72 transgenic mice have larger excitatory synapses with an increased amount of N-methyl-
d-aspartate (NMDA) receptors in the molecular layer of DG, compared with wild-type littermates. Furthermore, transgenic animals
have lower number of dentate granule cells with a parallel, but an even stronger decrease in the number of excitatory synapses in
the molecular layer. Importantly, we also show that treatment with N-acetylcysteine can effectively normalize all these changes
in transgenic animals, resulting in a state similar to wild-type mice. Our results show that G72 transcripts induce robust alterations in
the glutamatergic system at the synaptic level that can be rescued with N-acetylcysteine treatment.
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INTRODUCTION
Schizophrenia affects ~ 1% of the adult population.1 The disease is
characterized by a broad range of positive, negative and cognitive
symptoms. The exact pathogenesis of schizophrenia is unknown;
however, several signs indicate the role of a disturbed glutama-
tergic transmission in the prodromal phase of schizophrenia
causing memory and concentration deficits, as well as other
negative symptoms, which often precede the onset of the
disease.2,3 Glutamatergic synapses and N-methyl-d-aspartate-type
glutamate receptors (NMDARs) are the key participants in these
processes,4,5 and NMDAR antagonists reproduce negative, positive
and also many of the cognitive symptoms.6–8 Changes in the
glutamatergic system can also provoke a hyperdopaminergic state
in schizophrenia;9 however, amphetamine-induced hyperdopami-
nergic state causes only positive symptoms.10 Because currently
used antipsychotics (which antagonize dopaminergic/serotoner-
gic receptors) reduce mainly positive symptoms, the treatment of
negative and cognitive deficits is still a big challenge.11
Schizophrenia is highly heritable with several susceptibility
genes.12 One of the most frequently reported associations with
the disease is found at a locus on chromosome 13q32-q33
containing two overlapping genes, G72 and G30.13,14 These genes
appeared late during primate evolution, and are present only in
anthropoid primates.14 Analysis of serum and postmortem brain
samples of schizophrenic patients revealed an overexpression of
G72, compared with control subjects.15,16 Function of the longest
splice variant, LG72, remains controversial. It has been demon-
strated to bind D-amino acid oxidase (DAO), the main degrading
enzyme of NMDAR co-agonist D-serine,17 resulting in either
enhancement or depression of its enzymatic function.14,18,19
Furthermore, LG72 has been shown to be located in mitochondria,
influencing oxidative stress regulation20 and affecting mitochon-
drial morphology and dendritic arborization.21
To examine physiological effects of the encoded proteins of G72,
a ‘humanized’ transgenic mouse line was generated, carrying the
entire human G72/G30 genomic region. These transgenic mice
(G72Tg) encode splice variants similar to those present in the human
brain. G72Tg mice showed behavioral alterations that are expected
in a model of schizophrenia.22 They had an impaired spatial learning
ability, suggesting damaged hippocampal function,23 and G72
mRNA expression was among the highest in the dentate gyrus
(DG).22 Moreover, electrophysiological data revealed alterations at
excitatory perforant path synapses in the DG, where G72 is
expressed both in pre- and postsynaptic cells.23 Deformations of
DG are reported to be predictive for schizophrenia.24 Inadequate
maturation of dentate granule cells has been linked to neuropsy-
chiatric disorders,25 and further morphological, functional and
molecular dysfunctions of DG were observed in patients suffering
from schizophrenia26,27 and bipolar disorder.28 These disorders share
clinical features and genetic vulnerability,29 and G72 polymorphisms
also correlate with the onset of bipolar disorder.30
Growing evidence indicates the role of oxidative stress in the
generation of schizophrenia and bipolar disorder.31 In addition,
mitochondrial dysfunctions, especially at complex I, are repeatedly
observed in these disorders (see Discussion for details). LG72 can
bind to complex I, which has a central role in the generation of
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reactive oxygen species.32 Glutathione (GSH) is the main antiox-
idant of the brain. Compared with healthy control subjects,
patients suffering from schizophrenia or bipolar disorder have
significantly lower GSH levels.33,34 Interestingly, treatment with N-
acetylcysteine (NAC), a putative GSH precursor was shown to have
beneficial effects on negative symptoms of reported schizophrenic
cases,35,36 and on depressive symptoms in bipolar disorder.37,38
Similarly, G72Tg mice have decreased mitochondrial complex I
activity and lower GSH levels, and NAC treatment rescued the
above-mentioned spatial learning deficit in these G72Tg mice.23
In the present study, we reveal cellular and synaptic changes
that may explain the spatial learning deficits and electrophysio-
logical alterations of DG in the G72Tg animals. We demonstrate an
increase in the size and NMDAR content of excitatory synapses on
dentate granule cell spines, which is accompanied by a decrease
in the total number of excitatory synapses and granule cells in the
DG. Most importantly, oral treatment with NAC almost completely
restored these cellular and synaptic changes in G72Tg animals.
These results can provide an explanation for the effectiveness of
NAC treatment in human cases and can facilitate further research
to alleviate negative symptoms in patients suffering from
schizophrenia and bipolar disorder.
MATERIALS AND METHODS
Animals and tissue preparation
All experiments were performed in accordance with the institutional,
governmental and European Union guidelines. G72 transgenic mice
(G72Tg) were generated as described before.22 The ages of experimental
animals were the following: litter number 1 (L#1): 150 days (d), L#2: 39d,
L#3: 256d, L#4: 203d, L#5: 43d, L#6: 77d, L#7: 78d, L#8: 63d, L#9: 77d. After
weaning age (21d), NAC-treated mice received 1 mg ml− 1 NAC (A7250,
Sigma-Aldrich, St. Louis, MO, USA) dissolved in tap water as their only
drinking source for 6–8 weeks, whereas control mice drank tap water.
Drinking water was refreshed twice a week, and mice drank on average
10 ml liquid per day (no difference was observed between groups). Overall,
22 male CD1 mice—9 wild type and 13 transgenic, of which 4 were treated
with NAC—were anesthetized with inhalation of isoflurane, followed by
intraperitoneal injection of an anesthetic mixture (containing 8.3 mg ml− 1
ketamine, 1.7 mg ml− 1 xylazin-hydrochloride, 0.8 mg ml− 1 promethazi-
nium-chloride). Animals were perfused transcardially with 0.1 M phosphate
buffer (PB, pH 7.4), followed by fixative for 40 min and finally PB for 10 min.
Fixative contained 4% paraformaldehyde or 2% glutaraldehyde and 2%
paraformaldehyde in PB (for synapse morphology and synapse stereology
experiments). Coronal hippocampal sections were cut on Vibratome
(VT1200S, Leica Biosystems, Nussloch, Germany). Fifty-micrometer-thick
sections were washed in PB, cryoprotected in 30% sucrose solution, put in
vials, frozen in liquid nitrogen and stored at − 80 °C until further use. Two
hundred fifty-micrometer-thick sections were processed immediately for
freeze-substitution and low-temperature Lowicryl embedding directly after
perfusions.
Synapse morphology measurements
A series of 50-μm-thick sections—250 μm apart from each other—were
collected from the entire rostrocaudal extent of the hippocampi (from
Bregma − 0.95 mm, to − 4.03 mm) of 19 animals. After washing in PB,
sections were treated with 0.5% osmium-tetroxide for 20 min, were
dehydrated and embedded in Durcupan. During dehydration, sections
were treated with 1% uranyl acetate. After polymerization, we prepared
70-nm-thick sections (Leica EM UC6) from the outer two-thirds of the
molecular layer of DG, picked them up on formvar-coated single-slot
copper grids and examined them using a Hitachi H-7100 (Hitachi, Tokyo,
Japan) electron microscope (EM) and a Soft Imaging System Veleta CCD
camera (EMSIS, Münster, Germany). Synaptic area was measured from
serial sections of three-dimensional (3D) reconstructed synapses. We only
included synapses that were cut near perpendicularly to the sectioning
plane. After checking that the series of sections contained the whole
synapse, the synaptic area was calculated by measuring the length of the
synaptic active zone on each individual section of the same synapse, and
then the sum was multiplied by the thickness of the sections (70 nm). The
extent of the synaptic active zone was determined based on the extent of
the postsynaptic density (PSD). For measurements, we used ImageJ (Fiji).
For synaptic cleft width and PSD thickness measurements, synaptic and
postsynaptic grayscale values were investigated. The distance between the
two highest local grayscale maxima represented the actual synaptic cleft
width, and the distance between the highest postsynaptic local maximum
and the first local minimum represented the PSD thickness.
Post-embedding immunoelectron microscopy
Two hundred fifty-micrometer-thick sections from 11 animals were
cryoprotected in 10 and 30% sucrose solutions. After slam-freezing on
liquid nitrogen-cooled copper blocks, low-temperature dehydration was
started at − 90 °C with dried methanol containing 0.5% uranyl acetate for
24 h. Freeze substitution was performed at − 45 °C using ascending
mixtures of methanol and Lowicryl HM20 resin, and finally pure Lowicryl.
Then, resin was polymerized using ultraviolet light. Seventy-nanometer-
thick sections were picked up on formvar-coated single-slot nickel grids,
blocked for 1 h and incubated on drops of primary antibodies overnight.
The blocking solution, which was also used for diluting the primary and
secondary antibodies, contained 2% human serum albumin and 0.03%
Triton X-100 in Tris buffered saline. After incubation in primary antibody
(rabbit anti-GluN1, 1:30, gift of professor Masahiko Watanabe) for 18 h,
sections were washed in Tris buffered saline and incubated for 5 h on
drops of secondary antibody (10-nm gold particle-conjugated goat anti-
rabbit, British Biocell International, Cardiff, UK) diluted in blocking solution
(1:100), which contained polyethylene glycol (0.5 mg ml− 1). After washing
in ultrapure water, sections were contrasted with saturated aqueous uranyl
acetate. The specificity of the primary antibody has been tested by the
laboratory of origin.39 The omission of the primary antibody resulted in no
labeling. Forty-nanometer-wide bands were chosen on the two sides of the
postsynaptic membrane as an area representing postsynaptic membrane-
associated gold particle labeling. Synaptic areas were measured and
synaptic gold particles were counted on each 3D-reconstructed synapse.
Stereology
The total volume of the outer two-third of the DG molecular layer was
determined using the Stereo Investigator system (MBF Bioscience,
Williston, VT, USA) in nine animals. From this volume, small regions were
chosen randomly and 70-nm-thick section series were examined in EM
using the physical disector method. Asymmetric synapses were collected
within the counting frame (4 × 4–5 × 5 μm). From the physical disector
volume and number of synapses, we calculated synapse density, and
multiplied it by the volume of the outer two-third of the DG molecular
layer to get the total synapse number.
For the stereological measurement of the number of granule cells,
another systematic random series of 50-μm-thick sections—250 μm apart
from each other—were collected from the entire hippocampi of 12
animals. Sections were washed in PB, treated with 0.3% saponin in PB,
incubated in Mayer’s Hematoxylin solution (DAKO, Glostrup, Denmark;
diluted 1:20 in PB) for 30 min, washed in running tap water for 10 min,
rinsed in distilled water, washed in PB and mounted and coverslipped with
Aqua-Poly/Mount (Polysciences, Hirschberg an der Bergstrasse, Germany).
Stereology was performed on a Zeiss Axioskop 2 mot plus microscope,
using a Plan-Apochromat × 100/1.4 oil immersion objective, Q-Imaging
CCD camera and Stereo Investigator software (MBF Bioscience). The optical
fractionator method was used as described earlier.40 Section thickness was
checked in every counting frame (7 × 7 μm, height: 25 μm); x–y step size
was 100 μm. At least 7-μm-thick volume at the top and bottom of every
section was kept as guard zones.
Analysis
WT and G72Tg animals were selected randomly, after we identified litters,
in which sufficient numbers of both WT and G72Tg mice were present.
Sample sizes were estimated based on pilot investigations. In all five
experiments, described in the five Results sections, investigators were
blinded to the group allocations during the experiment and while
assessing the outcomes. Data populations with Gaussian distributions
(tested with Shapiro–Wilks W-test) were compared with parametric tests
and other distributions were compared with non-parametric tests. The
Mann–Whitney U-test was used for the analysis of synaptic area, synaptic
cleft width and PSD thickness. Spearman R correlation was used for the
analysis of the synaptic GluN1 content. Two sample t-test was used to
compare total synapse number of different groups, and Friedman test was
used for the analysis of granule cell numbers. The null hypothesis was
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rejected when the p-level was under 0.05, and, in such cases, the
differences were considered significant throughout this paper.
RESULTS
G72Tg animals have larger glutamatergic synapses in DG and it is
restored by NAC treatment
The synaptic active zone area of randomly sampled synapses was
measured in the outer two-thirds of the DG molecular layer
because this area is the termination zone of the perforant path,
and 85% of all asymmetric synapses here originate from these
fibers.41 Synapses were 3D-reconstructed from serial electron
microscopic sections (about two to five section per synapse;
Figure 1a), and synaptic areas were calculated accordingly (see
Materials and Methods).
First, we measured synaptic areas of five WT and G72Tg
littermate pairs, and found a significant increase of synaptic area
in G72Tg animals in all five investigated littermate pairs (L#1: WT:
n= 32 3D-reconstructed synapses, median = 25.97 × 103 nm2,
G72Tg: n = 24 synapses, median = 34.46 × 103 nm2, P= 0.013; L#2:
WT (n= 52, 24.25 × 103 nm2), G72Tg (n= 38, 30.89 × 103 nm2),
P= 0.024; L#3: WT (n= 43, 20.96 × 103 nm2), G72Tg (n= 28,
29.51 × 103 nm2), P = 0.014; L#4: WT (n = 24, 18.77 × 103 nm2),
G72Tg (n= 14, 29.95 × 103 nm2), P= 0.029; L#5: WT (n= 30,
21.26 × 103 nm2), G72Tg (n = 59, 28.09 × 103 nm2), P = 0.003). In
the pairwise comparisons of littermates, the median increase was
33%, min–max: 27–60% (Figure 1b). The ages of the littermates
(see Materials and Methods) did not correlate either with synaptic
area or with the extent of the observed changes (data not shown).
In the second set of experiments, we examined the effect of
NAC treatment on changes in synaptic areas (Figure 1c). We used
three groups of littermates, each consisting of a WT, a G72Tg and
a NAC-treated G72Tg (G72TgN) animal. We found again that
synaptic areas were significantly increased in G72Tg animals, and
values in each of these littermate groups significantly decreased
back to the normal level in NAC-treated G72TgN mice (L#6: WT
(n= 62, 23.61 × 103 nm2), G72Tg (n = 48, 28.83 × 103 nm2), G72TgN
(n= 87, 20.36 × 103 nm2), WT versus G72Tg P = 0.042, G72Tg versus
G72TgN Po0.001; L#7: WT (n= 69, 20.79 × 103 nm2), G72Tg
(n= 49, 35.33 × 103 nm2), G72TgN (n= 51, 27.68 × 103 nm2), WT
versus G72Tg Po0.001, G72Tg versus G72TgN P= 0.004; L#8: WT
(n= 60, 20.53 × 103 nm2), G72Tg (n = 56, 25.40 × 103 nm2), G72TgN
(n= 78, 22.14 × 103 nm2), WT versus G72Tg P= 0.046, G72Tg versus
G72TgN P = 0.031; Figure 1c).
Because synaptic areas of different mice in the same groups
(WT, G72Tg or G72TgN) did not differ significantly, we pooled
synaptic areas within these groups. The median synaptic area was
22.15 (interquartile range: 16.48–30.90) × 103 nm2 (n= 386) in WT
mice, 29.74 (21.74–43.00) × 103 nm2 (n= 316) in G72Tg mice and
21.89 (16.75–28.98) × 103 nm2 (n= 216) in G72TgN mice. This
means that the synaptic area increased by 33% in G72Tg animals,
compared with WT mice (Po0.001), and decreased by 35% (of WT
Figure 1. G72Tg mice have larger synapses, the sizes of which are normalized by N-acetylcysteine (NAC) treatment. (a) Electron micrographs
show representative glutamatergic excitatory synapses sampled from the outer two-thirds of the dentate gyrus molecular layer from wild-
type (WT, a’), G72 transgenic (G72Tg, a’’) and NAC-treated G72 transgenic (G72TgN, a’’’) animals (synaptic active zone edges are indicated with
arrows). Scale bar: 200 nm for all images. (b, c) Dots represent the median values of 3D-reconstructed synaptic areas in individual animals, and
whiskers mark 40–60 percentile boundaries. Effects were tested in five littermate pairs (b, their values are connected) and in three littermate
pairs (c), and then the G72 effect was reversed by the NAC treatment in G72TgN littermates (c; *Po0.05). Numbers indicate litters. Litter
number 1 (L#1): WT: n= 32 3D-reconstructed synapses, G72Tg: n= 24, P = 0.013; L#2: (n= 52, 38), P = 0.024; L#3: (n= 43, 28), P = 0.014; L#4:
(n= 24, 14), P= 0.029; L#5: (n = 30, 59), P = 0.003; L#6: WT (n= 62), G72Tg (n= 48), G72TgN (n = 87), WT versus G72Tg P = 0.042, G72Tg versus
G72TgN Po0.001; L#7: (n= 69, 49, 51), WT versus G72Tg Po0.001, G72Tg versus G72TgN P = 0.004; L#8: (n= 60, 56, 78), WT versus G72Tg
P= 0.046, G72Tg versus G72TgN P = 0.031.
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values) in NAC-treated G72TgN mice compared with G72Tg
animals (Po0.001). These results show that the G72 gene strongly
affects synapses, and the NAC treatment can completely reverse
these effects.
Larger synapses contain more NMDA receptors in G72Tg animals
as well
NMDARs have heterotetrameric structure with two obligatory
GluN1 subunits.39,42 Because NMDAR content correlates with
synaptic area, larger synapses contain more NMDARs.43,44 To
confirm that such a correlation exists here as well, we carried out
quantitative post-embedding immunogold experiments, using a
GluN1 subunit-specific antibody. Synaptic area increase in G72Tg
animals and the effect of the NAC treatment on synaptic areas
could also be observed in these experiments (Figure 2a). We found
that synaptic areas and their NMDAR content showed significant
correlations (Figure 2b) in WT (Po0.001, Spearman R= 0.404,
n= 94 3D-reconstructed synapses), G72Tg (Po0.001, R= 0.438,
n= 118) and G72TgN animals (Po0.001, R= 0.346, n= 129) and
also when these data were pooled (Po0.001, R= 0.385). Accord-
ing to the latter correlation, 33% increase in synaptic area
(described above) corresponds to an ~ 22% increase in synaptic
NMDAR content in G72Tg mice.
Synaptic cleft width and PSD thickness are unchanged in G72Tg
animals
Certain types of synaptic plasticity can influence synaptic
scaffolding and synaptic adhesion molecules and can, therefore,
influence cleft width and the thickness of PSD. We compared
these features between WT and G72Tg animals. Asymmetric
synapses were sampled from the outer two-thirds of the DG
molecular layer, and examined in the electron microscopic images
(Figures 3a and b). The width of the synaptic cleft and the
thickness of PSDs were determined by an unbiased algorithm,
using the grayscale levels (Figure 3c). We found that neither cleft
width (P= 0.996) nor PSD thickness (P = 0.711) have changed in
the G72Tg mice (Figure 3d). The median synaptic cleft width was
18.0 nm (interquartile range: 16.2–19.8) and PSD thickness was
100.08 nm (88.96–122.32) in WT mice (n = 44 synapses from two
mice). The median synaptic cleft was 18.0 nm (14.4–21.6) and PSD
thickness was 97.30 nm (87.57–123.71) in the G72Tg mice (n = 36
synapses from two mice).
G72Tg animals have fewer synapses in DG and it is restored by
NAC treatment
We tested whether the expression of the G72 gene affects the
number of synapses. Using quantitative stereological measure-
ments with physical disector method, we estimated the number of
synapses in the perforant path recipient outer two-thirds of the
DG molecular layer (Figures 4a and b) in three triplets of
littermates (L#6–8), by taking 18 volume samples per groups
(WT, G72Tg, G72TgN). Compared with WT mice (mean=
41.98 × 108, s.d. = ± 7.77 × 108, a total of n = 444 synapses counted),
synapse number decreased in G72Tg mice (mean= 32.38 × 108, s.
d. = ± 1.07 × 109, n = 327, WT versus G72Tg P= 0.004) and restored
near to the normal level after NAC treatment (mean= 41.04 × 108,
s.d. = ± 1.08 × 109, n= 417, G72Tg versus G72TgN P= 0.021,
Figure 4c).
G72Tg animals have fewer granule cells in DG and it is restored by
NAC treatment
Using quantitative stereological measurements with optical
fractionator method (Figures 4d and e), we tested whether the
expression of the G72 gene affects the number of granule cells in
DG. Estimations are given for one brain hemisphere in four groups
of littermates. Compared with WT mice, the number of cells
decreased in all G72Tg mice (with a median of 9%) and restored
near to the normal level after NAC treatment (with a median of
Figure 2. Correlation between synaptic N-methyl-d-aspartate (NMDA) receptor content and synaptic area is unaffected by genotype and N-
acetylcysteine (NAC) treatment. (a) Electron micrographs show representative glutamatergic synapses sampled from the outer two-thirds of
the dentate gyrus molecular layer from wild-type (WT, a’), G72 transgenic (G72Tg, a’’) and NAC-treated G72 transgenic (G72TgN, a’’’) animals
(synaptic active zone edges are indicated with white bars). Post-embedding immunogold labeling against GluN1 NMDA receptor subunit
(arrows). Scale bar: 150 nm for all images. (b) Scatterplots show significant (Po0.01) correlations between synaptic immunogold particle
number and synaptic active zone area in WT (Spearman R= 0.404, n= 94 3D-reconstructed synapses), G72Tg (R= 0.438, n= 118), G72TgN
(R= 0.346, n = 129) mice, as well as when data were pooled (R= 0.385, n= 341). Animals used for these measurements were taken from litters
L#3, L#4, L#6, L#7 and L#8.
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7%). The values were 62.13 (WT, n= 380 sample of cells), 56.96
(G72Tg, n = 349) and 60.03 (G72TgN, n= 374) × 104 cells in the first
group (L#6); 68.98 (WT, n = 369), 62.22 (G72Tg, n= 335) and 68.13
(G72TgN, n= 370) × 104 cells in the second group (L#7); 79.55 (WT,
n= 392), 61.87 (G72Tg, n = 344) and 66.44 (G72TgN, n= 352) × 104
cells in the third group (L#8); and 57.98 (WT, n= 297), 56.56
(G72Tg, n = 324) and 61.39 (G72TgN, n= 348) × 104 cells in the
fourth group (L#9) of littermates (Figure 4f). These changes among
littermates are statistically significant (P= 0.039).
DISCUSSION
Here we demonstrated that G72 gene expression in a humanized
schizophrenia model mouse induces synaptic and cellular
changes, and found that these changes are normalized by NAC
treatment. Our major findings are that (1) in G72Tg mice,
glutamatergic synapses are significantly larger in the main input
zone of DG compared with WT littermates and (2) these larger
synapses contain more NMDA receptors, whereas receptor density
remains unchanged. On the other hand, (3) the number of
excitatory synapses targeting DG granule cell spines is decreased
in G72Tg animals and (4) there are fewer granule cells in DG. (5)
Most importantly, treatment with NAC was efficient in normalizing
all these alterations, suggesting that oxidative stress has a major
role in G72 gene-induced pathology.
G72 gene polymorphisms confer susceptibility to
schizophrenia13 and bipolar disorder.29,30,45 Schizophrenic
patients with G72 gene polymorphisms have an elevated level
of LG72 protein in the brain and plasma.15,16 G72Tg mice express
G72 transcripts similar to those in humans, including the longest
open reading frame, LG72.22 Expression of G72 transcripts was
highest in DG,22 a brain area frequently affected in schizophrenia
and bipolar disorder (see Introduction). G72Tg mice show
schizophrenia-like behavioral alterations, including a massive
DG-dependent deficit in spatial learning ability.23 These hippo-
campal circuits, responsible for learning and memory, are mainly
glutamatergic. The ‘glutamate hypothesis’ of schizophrenia
suggests a dysregulation of the glutamatergic system with a
hypofunction of NMDA-type ionotropic glutamate receptors,
along with changes in the number of NMDARs in specific brain
regions.4,5 In schizophrenia, many glutamate-regulated processes
seem to be perturbed, which lead to a decreased number of
excitatory synapses resulting in insufficient neuronal circuits.2 This
is exactly what we found in G72Tg mice. Similar changes may
occur in patients with G72 gene polymorphisms with conse-
quently higher LG72 protein levels.
Unlikely effect of G72 on DAO in DG
Previously, LG72 was considered to be a modulator of the
D-serine-degrading enzyme, DAO.14,18,19 D-serine and glycine are
NMDAR co-agonists that have a common binding site on NMDARs.
In the hippocampal formation, D-serine seems to be the main co-
agonist of NMDARs because its density is high in the hippocampus
and the outer two-thirds of the DG molecular layer, whereas
glycine is absent in these regions.46,47 D-serine is essential for the
physiological function of the adult DG and it is also necessary for
full NMDAR function.48 A reduction in D-serine levels can be
observed in patients with schizophrenia49,50 and treatment with
this amino acid results in ameliorated symptomatology.51,52
However, only low levels of DAO are present in the molecular
Figure 3. Synaptic cleft width and postsynaptic density (PSD) thickness are unchanged in G72 transgenic animals. (a) Electron micrograph of a
glutamatergic synapse sampled for measurement. Scale bar: 150 nm. (b) Area selected for measurements (white box in a). (c) Line graph
shows vertically summed optical density values of the synapse shown in b. (d) Synaptic cleft width (P= 0.996) and PSD thickness (P= 0.711) did
not differ between wild type (WT; n = 44 synapses from two mice) and G72Tg (n= 36 synapses from two mice) mice. The median values and
interquartile ranges are shown. Animals used for these measurements were taken from litters L#3 and L#4.
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layer of DG,53 and the decrease in the D-serine level observed in
aging or under pathological conditions is probably because of an
impairment in serine racemase activity54 rather than because of
DAO. Therefore, it is unlikely that the changes observed in this
study are consequences of G72-triggered altered DAO activity.
Possible role of G72 in the regulation of oxidative stress
LG72 has been shown to be located in mitochondria.21 Recently,
the mitochondrial enzyme methionine-R-sulfoxide reductase B2
has been identified as a binding partner of LG72, suggesting that
LG72 can influence oxidative stress regulation.20 Subcellular
localization and the ability of LG72 to bind flavin-containing
proteins also suggest a connection between LG72 and complex I
of the mitochondrial respiratory chain.23 Complex I is often
affected in schizophrenia and bipolar disorder.55,56 Impaired
complex I function results in increased generation of reactive
oxygen species.32 Because complex I is highly susceptible to
oxidative damage,57 this leads to a vicious circle and results in the
depletion of antioxidants. Consequent oxidative stress has a role
in the generation of both schizophrenia and bipolar disorder.58–60
This is represented as a reduction in the GSH level in patients
suffering from these diseases.33,34 G72 transgenic mice show signs
of altered mitochondrial function and oxidative stress.23,61
Furthermore, these mice also possess decreased complex I activity
and a reduction in the GSH level.23 The effectiveness of the
putative GSH precursor NAC in ameliorating cognitive,23 cellular
and subcellular alterations of G72Tg mice (present study) confirms
the possible role of G72 transcripts in the regulation of oxidative
stress.
NMDARs have a redox-sensitive modulatory site. Oxidative
environment can inhibit NMDAR function up to 50%.62 Depleted
GSH level does also have a direct effect on NMDARs,63 whereas
the GSH level is decreased in G72Tg mice, similar to patients
suffering from schizophrenia or bipolar disorder. Although we did
not assess NMDAR hypofunction here directly, the potential link
between NMDAR hypofunction and oxidative stress in the
pathogenesis of schizophrenia has also been proposed before.64
Here, we hypothesize that larger synapses with more NMDARs
observed in the molecular layer of G72Tg mice are a response to
NMDAR hypofunction due to oxidative damage. These larger
synapses are necessary and sufficient to maintain basal synaptic
activity; however, they are unable to adapt to further potentiation
demands, resulting in decreased plasticity and cognitive deficits of
these mice. In addition, although changes in the synaptic
structural profile often accompany physiological alterations of
neurons,65–67 we found no difference in synaptic cleft width or
PSD thickness of G72Tg mice compared with WT animals, further
suggesting an intact synaptic architecture, but changed NMDAR-
related functions.
Furthermore, damaged presynaptic mitochondrial activity may
also have a role in the observed changes. Electrophysiological
investigations of these synapses revealed unchanged basal
activity, but a deficit in sustaining high-frequency transmission
and in paired-pulse facilitation,23 suggesting a presynaptic
impairment and damaged mitochondrial function. This may also
Figure 4. The number of synapses and granule cells decreased in G72Tg mice, and it was normalized by N-acetylcysteine (NAC) treatment. (a)
Light micrograph shows a hippocampal section before measurements. White dashed line marks the molecular and granule cell layer border of
the dentate gyrus, stripes indicate the outer two-thirds of the molecular layer, from where the samples were collected. (b) Electron micrograph
shows an image from a series used for physical disector method. Green/red lines show the stereological counting frame (5 × 5 μm). (c) The
number of synapses in the outer two-thirds of the molecular layer is decreased in G72Tg mice. This effect is reversed by NAC treatment in
G72TgN mice. Dots represent individual measurements (n = 18 in each group), lines represent the mean values (WT: 41.98 × 108, s.
d.=± 7.77 × 108; G72Tg: 32.38 × 108, s.d.=± 1.07 × 109; G72TgN: 41.04 × 108, s.d.=± 1.08 × 109). WT versus G72Tg P = 0.004, G72Tg versus
G72TgN P= 0.021. Total number of synapses counted during stereological measurements: WT: 444 synapses, G72Tg: 327 synapses, G72TgN:
417 synapses. (d) Light micrograph shows the dentate gyrus. White dashed line marks the granule cell layer (the sampling area). (e) Light
micrograph from optical fractionator measurement. Green/red lines: stereological counting frame (7 × 7 μm). Hematoxylin-labeled nuclei of
granule cells (purple) were counted. (f) Number of granule cells is decreased in G72Tg mice, which is reversed by NAC treatment (*, Friedman
test Po0.05). Note that the optical fractionator method used in this experiment results in a single final value for every individual animal
investigated (dots). Values connected by lines correspond to littermates. Numbers indicate litters. Litter number 6 (L#6): WT: number of cells
counted during measurement: n = 380, G72Tg (n= 349), G72TgN (n= 374); L#7: n= 369, 335, 370; L#8 n= 392, 344, 352; L#9: n= 297, 324, 348.
Data are given for one brain hemisphere in all cases.
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result in a postsynaptic compensatory change that helps to
maintain a certain level of synaptic activity by increasing synaptic
size and receptor content.
We found a decrease in the number of granule cells (~9%
decrease) and an even larger decrease in their synapses (~23%
decrease), which suggests that the decline in the number of
granule cells does not account for all the losses of excitatory
synapses on their dendrites. This means that, on average, each
individual granule cell receives less glutamatergic input in G72Tg
animals compared with WT mice. The observed changes may be
either because of an NMDAR hypofunction or are directly induced
by oxidative stress in the DG. Granule cells are continuously
generated in DG, even in adulthood, and newborn cells are
indispensable for circuit formation and essential for intact learning
and memory processes.68 The survival of newborn neurons
depends on proper NMDAR function.69 On the other hand,
neurogenesis is highly sensitive to oxidative stress.70,71 Further-
more, oxidative environment promotes the aging of cells, short-
ening their lifetime.71 Decreased neurogenesis has been linked to
schizophrenia,72 whereas neuronal atrophy is thought to accom-
pany bipolar disorder.73 These processes can lead to a lower
number of dentate granule cells, which we found in G72Tg
animals, whereas insufficient synaptic connectivity in the DG may
be responsible for impaired spatial learning ability of these mice.
Beneficial effects of NAC treatment
NAC is currently used in acetaminophen overdose and as a
mucolytic agent. It provides protection against oxidative stress,
can enhance cystine-glutamate antiporter, reduce inflammatory
cytokines and has been trialed in several psychiatric disorders.74
NAC was effective in bipolar disorder,37,38 and also in ameliorating
negative symptoms in patients with schizophrenia.35,36 In G72Tg
animals, the reduced GSH level could be rescued by treatment
with NAC.23
In the present study, we have shown that oral NAC treatment
can effectively normalize cellular and synaptic alterations of G72Tg
mice, and we present the first high-resolution anatomical
evidence that NAC can directly act at cellular and synaptic levels.
If the presence of G72-susceptibility polymorphisms could be
routinely detected by responsible genetic profiling in schizo-
phrenia or bipolar disorder patients, NAC treatment could provide
a personalized causal treatment for deficits caused by G72
polymorphisms, and these human patients may see an improve-
ment in negative and cognitive deficits—a field where most
current antipsychotics fail. These beneficial effects could be
achieved with the repurposing of a cheap, simple and safe drug,
which is already used in other fields of medicine.
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